US4599353A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
Assignee: Columbia University
•
Filing: 1982-05-03
•
Granted: 1986-07-08
•
Expires: 2002-05-03
Abstract
Abstract Ocular hypertension and glaucoma can be effectively controlled in primates through topical application of an effective amount of an eicosanoid or an eicosanoid derivative to the surface of an afflicted eye. Eicosanoids, particularly the prostaglandins PGE2 and PGF2 alpha , and derivatives thereof, have been found effective in quantities less than about 1000 mu g per eye. Ophthalmic compositions containing C1 to C5 alkyl esters of PGF2 alpha are presently preferred for use in treating ocular hypertension and glaucoma in primates, including man.
Inventors
- 👤 Laszlo Z. Bito
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-29 03:40
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/557; A61P; A61P27/00; A61P27/02; A61P27/06
Claims Analysis
Total Claims: 22
Claim 1
Independent Claim
52 words
A method for treating hypertension or glaucoma in a primate subject's eye comprising periodically contacting the surface of the eye with an amount of an eicosanoid or an eicosanoid derivative effective to reduce intraocular pressure in the eye without any substantial initial increase in said pressure and to maintain reduced intraocular pressure.
Claim 2
Independent Claim
52 words
A method for treating hypertension or glaucoma in a primate subject's eye comprising periodically contacting the surface of the eye with an amount of an eicosanoid or an eicosanoid derivative effective to reduce intraocular pressure in the eye without any substantial initial increase in said pressure and to maintain reduced intraocular pressure.
Claim 3
Dependent Claim
14 words
The method of claim 1 wherein the surface of the eye is contacted daily.
Claim 4
Dependent Claim
18 words
The method of claim 1 wherein the eicosanoid or eicosanoid derivative is a prostaglandin or a prostaglandin derivative.
Claim 5
Dependent Claim
19 words
The method of claim 3 wherein the prostaglandin or prostaglandin derivative is PGE 2 or a PGE 2 derivative.
Claim 6
Dependent Claim
21 words
The method of claim 3 wherein the prostaglandin or prostaglandin derivative is PGF 2 α or a PGF 2 α derivative.
Claim 7
Dependent Claim
24 words
The method of claim 5 wherein the PGF 2 α derivative is a C 1 to C 5 alkyl ester of PGF 2 α.
Claim 8
Dependent Claim
33 words
The method of claim 6 wherein the PGF 2 α derivative is PGF 2 α methyl ester, PGF 2 α ethyl ester, PGF 2 α isopropyl ester, or PGF 2 α isobutyl ester.
Claim 9
Dependent Claim
18 words
The method of claim 5 wherein the PGF 2 α or PGF 2 α derivative is lipid soluble.
Claim 10
Dependent Claim
28 words
The method of claim 5 wherein the PGF 2 α or PGF 2 α derivative is in the form of a physiologically acceptable salt of PGF 2 α.
Claim 11
Dependent Claim
16 words
The method of claim 9 wherein the PGF 2 α salt is PGF 2 α tromethamine.
Claim 12
Dependent Claim
25 words
The method of claim 3 wherein the amount of prostaglandin or prostaglandin derivative is in the range from about 0.01 μg to about 1,000 μg.
Claim 13
Dependent Claim
25 words
The method of claim 11 wherein the amount of prostaglandin or prostaglandin derivative is in the range from about 0.1 μg to about 500 μg.
Claim 14
Dependent Claim
46 words
A composition for topical treatment of glaucoma in the eye of a primate subject comprising an effective amount of PGF 2 α methyl ester, PGF 2 α ethyl ester, PGF 2 α isopropyl ester, or PGF 2 α isobutyl ester dissolved in an ophthalmically compatible carrier.
Claim 15
Dependent Claim
46 words
A composition for topical treatment of glaucoma in the eye of a primate subject comprising an effective amount of PGF 2 α methyl ester, PGF 2 α ethyl ester, PGF 2 α isopropyl ester, or PGF 2 α isobutyl ester dissolved in an ophthalmically compatible carrier.
Claim 16
Dependent Claim
32 words
A composition for the topical treatment of glaucoma in a primate subject's eye comprising an effective amount of a lower alkyl ester of PGF 2 α dissolved in an ophthalmically compatible carrier.
Claim 17
Dependent Claim
32 words
A composition for the topical treatment of glaucoma in a primate subject's eye comprising an effective amount of a lower alkyl ester of PGF 2 α dissolved in an ophthalmically compatible carrier.
Claim 18
Dependent Claim
39 words
A method for topically treating glaucoma in a primate subject's eye comprising contacting daily the surface of the eye with about 50 μl of a composition of claim 14 which is a lower alkyl ester of PGF 2 α.
Claim 19
Dependent Claim
17 words
A composition of claim 14, wherein the lower alkyl ester is C 1 to C 5 .
Claim 20
Dependent Claim
13 words
A composition of claim 14, wherein the carrier is sterile anhydrous peanut oil.
Claim 21
Dependent Claim
12 words
A composition of claim 14, wherein the carrier is sterile mineral oil.
Claim 22
Dependent Claim
18 words
A composition of claim 14, wherein the effective amount is from about 0.01% to about 1.0% by weight.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1989-07-07 | 1990-01-06 | 1990-07-08 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1993-07-07 | 1994-01-06 | 1994-07-08 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1997-07-07 | 1998-01-06 | 1998-07-08 | $7700.00 | Window Closed / Lapsed |